Preferences help
enabled [disable] Abstract
Number of results
2012 | 7 | 4 | 429-434
Article title

Alendronate in patients with calcium nephrolithiasis and loss of bone mass

Title variants
Languages of publication
Physical description
1 - 8 - 2012
24 - 5 - 2012
  • Urology Department, San Cecilio University Hospital, 18003, Granada, Spain
  • Urology Department, San Cecilio University Hospital, 18003, Granada, Spain
  • Medicine Department, Granada University, 18003, Granada, Spain
  • Urology Department, San Cecilio University Hospital, 18003, Granada, Spain
  • [1] Arrabal Martín M, Fernández Rodríguez A, Arrabal Polo MA, Ruíz García MJ, Zuluaga Gómez A. Study of the physical-chemical factors in patients with renal lithiasis. Arch Esp Urol. 2006; 59:583–594
  • [2] Arrabal Martín M, Díaz de la Guardia FV, Jiménez Pacheco A, López León V, Arrabal Polo MA, Zuluaga Gómez A. The treatment of renal lithiasis with biphosphonates. Arch Esp Urol. 2007; 60:745–754[Crossref]
  • [3] Thorleifsson G, Holm H, Edvardsson V, Walters GB, Styrkarsdottir U, Gudbjartsson DF et al. Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet. 2009; 41:926–930[WoS][Crossref]
  • [4] Cipriani Thorne E. Osteoporosis: Consideraciones diagnosticas y terapeuticas. Rev Med Hered. 2004; 15:101–107
  • [5] Moro-Alvarez MJ, Cabrera JA. Osteoporosis in men. Rev Clin Esp. 2010; 210:342–349[Crossref]
  • [6] Morales Piga A. Advances in the treatment of osteoporosis at the beginning of the new millennium. Rev Clin Esp. 2002; 202:23–26 [Crossref][PubMed]
  • [7] Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010; 95:1555–1565[Crossref]
  • [8] Adrover Rigo M, Juste Diez de Pinos JL, Tuset Creus M, Codina Jane C, Ribas Sala J. Revision clínica de la utilización de los bifosfonatos. Farm Hosp. 2000; 24:74–82
  • [9] Ravn P. Bisphosphonates for prevention of postmenopausal osteoporosis. Dan Med Bull. 2002; 49:1–18 [PubMed]
  • [10] Bonnick S, Broy S, Kaiser F, Teutsch C, Rosenberg E, DeLucca P et al. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density. Curr Med Res Opin. 2007; 23:1341–1349[WoS][Crossref]
  • [11] Ravn P, Clemmesen B, Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone. 1999; 24:237–244 [Crossref]
  • [12] Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J et al. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab. 2001; 86:1116–1125[Crossref]
  • [13] Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther. 2007; 29:1548–1558[WoS][Crossref]
  • [14] Abrahamsen B. Bisphosphonate adverse effects, lessons from large databases. Curr Opin Rheumatol. 2010; 22:404–409[WoS][Crossref]
  • [15] Venkatanarasimha N, Miles G, Suresh P. Subtrochanteric femoral insufficiency fractures related to the use of long-term biphosphonates: a pictorial review. Emerg Radiol. 2010; 17:511–515[Crossref]
  • [16] Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab. 2010; 95:5258–5265[Crossref][WoS]
  • [17] Arrabal-Martín M, Fernández-Rodríguez A, Arrabal-Polo MA, García-Ruiz MJ, Zuluaga-Gómez A. Extracorporeal renal lithotripsy: evolution of residual lithiasis treated with thiazides. Urology. 2006; 68:956–959[Crossref]
  • [18] Sakhaee K, Maalouf N, Kumar R, Pasch A, Moe O. Nephrolithiasis-associated bone disease: pathogenesis and treatment options. Kidney Int. 2011; 79:393–403[WoS][Crossref]
  • [19] Legroux-Gerot I, Catanzariti L, Marchandise X, Duquesnoy B, Cortet B. Bone mineral density changes in hypercalciuretic osteoporotic men treated with thiazide diuretics. Joint Bone Spine. 2004; 71:51–55[Crossref]
  • [20] Bushinsky DA, Neumann KJ, Asplin J, Krieger NS. Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats. Kidney Int. 1999; 55:234–243[Crossref]
  • [21] Ruml LA, Dubois SK, Roberts ML, Pak CY. Prevention of hypercalciuria and stone-forming propensity during prolonged bedrest by alendronate. J Bone Miner Res. 1995; 10:655–662[Crossref]
  • [22] Heller HJ, Zerwekh JE, Gottschalk FA, Pak CY. Reduced bone formation and relatively increased bone resorption in absorptive hypercalciuria. Kidney Int. 2007; 71:808–815[WoS][Crossref]
  • [23] Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E et al. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments. Nephrol Dial Transplant. 2009; 24:1472–1477[Crossref]
  • [24] Chandhoke PS. When is medical prophylaxis cost-effective for recurrent calcium stones? J Urol. 2002; 168:937–940[Crossref]
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.